- Home
- AMZE vs COCP Comparison
AMZE vs COCP Comparison
Compare AMZE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | COCP |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 15.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | AMZE | COCP |
|---|---|---|
| Price | $0.13 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 9.0M | 124.6K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.86 |
| 52 Week High | $11.76 | $2.19 |
Technical Indicators
Market Signals| Indicator | AMZE | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 35.64 |
| Support Level | $0.11 | $1.00 |
| Resistance Level | $0.20 | $1.27 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 14.24 | 6.80 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).